Table 2. Serology testing results from non-encephalitic acute febrile illness patients with confirmed JEV, probable JEV, DENV, and flavivirus infection.
No. | Patient sample ID | Age (years) | Days after onset | IgM | PRNT90 titer | |||||
---|---|---|---|---|---|---|---|---|---|---|
JEVa | DENVb | JEV | DENV-1 | DENV-2 | DENV-3 | DENV-4 | ||||
JEV (confirmed) | ||||||||||
1 | WGY599 S1 | 20 | 3 | − | − | 40 | <10 | <10 | <10 | <10 |
WGY599 S2 | 6 | + | + | 1,280 | 20 | 80 | 20 | 20 | ||
2 | WGY623 S1 | 32 | 3 | − | − | <10 | <10 | <10 | <10 | <10 |
WGY623 S2 | 7 | + | + | 640 | 40 | 40 | 80 | 80 | ||
3 | WGY656 S1 | 23 | 2 | EQU | − | 20 | <10 | 80 | 10 | 20 |
WGY656 S2 | 3 | + | − | >320 | 40 | 40 | 40 | NA | ||
4 | WGY726 S1 | 32 | 7 | + | + | 80 | 10 | 40 | 80 | 10 |
WGY726 S2 | 10 | + | + | 320 | 10 | 40 | 20 | 20 | ||
5 | WGY733 S1 | 15 | 4 | − | − | 80 | <10 | 40 | 80 | 20 |
WGY733 S2 | 7 | + | + | 320 | 10 | 40 | 80 | 20 | ||
JEV (probable) | ||||||||||
6 | WGY067 S1 | 22 | 4 | QNS | − | 40 | 160 | 80 | 80 | 80 |
WGY067 S2 | 7 | + | − | 80 | >2,560 | 160 | 160 | 160 | ||
7 | WGY143 S1 | 4 | 7 | QNS | − | 40 | 640 | 80 | 80 | 20 |
WGY143 S2 | 12 | EQU | − | 160 | >2,560 | 160 | 160 | 80 | ||
8 | WGY317 S1 | 47 | 5 | + | − | 40 | <10 | 80 | 10 | 40 |
WGY317 S2 | 8 | + | − | 80 | <10 | 160 | 10 | 80 | ||
9 | WGY629 S1 | 19 | 5 | + | − | 160 | 20 | 160 | 80 | 160 |
WGY629 S2 | 7 | + | − | 320 | 320 | 1,280 | 160 | 320 | ||
10 | WGY647 S1 | 27 | 5 | + | − | 80 | 160 | 80 | 40 | 80 |
WGY647 S2 | 6 | + | − | 160 | 1,280 | 20 | 160 | 80 | ||
11 | WGY658 S1 | 30 | 3 | EQU | − | <10 | 40 | <10 | <10 | 10 |
WGY658 S2 | 5 | EQU | − | 80 | 80 | <10 | <10 | <10 | ||
12 | WGY667 S1 | 6 | 5 | EQU | − | 20 | <10 | 20 | 10 | 40 |
WGY667 S2 | 7 | + | − | 160 | 20 | 160 | 160 | 160 | ||
13 | WGY713 S1 | 72 | 3 | EQU | − | 10 | NA | 40 | NA | NA |
WGY713 S2 | 8 | EQU | − | 80 | 40 | 320 | 40 | 40 | ||
DENV | ||||||||||
14 | WGY065 S1 | 33 | 5 | QNS | − | 320 | 160 | 160 | 320 | 160 |
WGY065 S2 | 8 | + | + | 320 | >2,560 | >2,560 | >2,560 | 160 | ||
15 | WGY071 S1 | 16 | 4 | QNS | − | 20 | 10 | 40 | 160 | 20 |
WGY071 S2 | 7 | + | + | 20 | 80 | 160 | >2,560 | 80 | ||
16 | WGY321 S1 | 24 | 5 | − | − | 160 | 160 | 40 | 80 | 20 |
WGY321 S2 | 7 | + | + | 160 | 1280 | 160 | 160 | 80 | ||
17 | WGY724 S1 | 28 | 4 | EQU | − | <10 | 40 | 10 | 20 | 10 |
WGY724 S2 | 7 | EQU | + | 20 | 80 | 160 | 80 | 80 | ||
18 | WGY727 S1 | 19 | 5 | − | + | 20 | 40 | 40 | 40 | 40 |
WGY727 S2 | 6 | EQU | + | 160 | >2,560 | 80 | 80 | 160 | ||
Flavivirus | ||||||||||
19 | WGY089 S1 | 33 | 5 | QNS | + | 40 | 20 | 80 | 80 | 40 |
WGY089 S2 | 8 | + | + | 80 | 20 | 80 | 160 | 40 | ||
20 | WGY174 S1 | 3 | 4 | + | + | 40 | 10 | 80 | 80 | 160 |
WGY174 S2 | 5 | + | + | 320 | 10 | 320 | 80 | 320 | ||
21 | WGY178 S1 | 20 | 3 | + | − | 80 | 40 | 80 | <10 | <10 |
WGY178 S2 | 5 | + | + | 160 | 40 | 320 | 20 | 20 | ||
22 | WGY516 S1 | 15 | 3 | QNS | + | <10 | <10 | <10 | 40 | <10 |
WGY516 S2 | 5 | EQU | + | 20 | <10 | <10 | 40 | <10 | ||
23 | WGY575 S1 | 26 | 4 | EQU | − | 20 | 20 | 40 | 20 | 10 |
WGY575 S2 | 5 | + | + | 160 | 40 | 80 | 160 | 40 | ||
24 | WGY674 S1 | 21 | 5 | − | − | 40 | <10 | <10 | <10 | <10 |
WGY674 S2 | 7 | + | + | 40 | 10 | 20 | <10 | 20 | ||
25 | WGY684 S1 | 16 | 5 | + | + | 80 | <10 | 10 | 40 | 10 |
WGY684 S2 | 6 | + | + | 80 | 10 | 20 | 40 | 20 | ||
26 | WGY708 S1 | 31 | 3 | + | − | NA | NA | NA | NA | NA |
WGY708 S2 | 6 | + | + | 40 | 40 | 40 | 20 | 40 |
aRatios of samples optical densities divided by negative control were calculated; <2, negative (−); 2–3 equivocal (EQU); >3 positive (+).
bCalculated ELISA binding index results ≥40 U were considered positive (+), while <40 U were considered negative (−).
S1, admission serum sample; S2, discharge serum sample; QNS, quantity not sufficient.